Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13

6 juin 2018

09:00
PENTAX Medical Company, a healthcare industry leader in diagnostic and therapeutic endoscopy, announced today the results about the C2 CryoBalloontm Ablation System's clinical efficacy, durability, and patient tolerability from various studies...

09:00
At the American Headache Society's (AHS) 60th Annual Scientific Meeting, leading researchers specializing in migraine, cluster headache and post-traumatic headache, will present groundbreaking data on innovative pharmacological and...

09:00
FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement...

09:00
Israeli biotechnology company Kadimastem announced that its scientific research has been published in the prestigious medical journal Stem Cell Research and Therapy. The link to the article is:...

08:59
Thermi®, an Almirall S.A. company, today announced that its ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in the peer-reviewed journal...

08:30
SCYNEXIS, Inc. , a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a Phase 1 study of SCY-078, assessing the risk for drug-drug...

08:00
Iterum Therapeutics plc , a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, will present four posters at the American Society of Microbiology MICROBE meeting in Atlanta from June 7 - 10, 2018....

08:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that topline results from the pivotal QuANTUM-R phase 3 study of single agent quizartinib will be presented for the first time at the 23rd Congress of the European Hematology...

07:00
Alkermes plc today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (diroximel fumarate)....

02:53
On April 22, 2018, the 4th annual China-US Innovation Competition hosted by Entrepreneur Foundation (www.bsef.us) successfully took place in Questrom School of Business at Boston University. After the preliminary review, 8 finalists were selected...

00:00
Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial HOPE-1 (Hydration for Optimal Pulmonary Effectiveness), which showed that treatment with SPX-101 in patients with cystic fibrosis (CF) resulted in a...


5 juin 2018

17:56
More than 16 million people in the United States are affected by diabetes, a metabolic condition resulting in high blood sugar levels. A new research article published in the June 1, 2018 issue of the Journal of the American Academy of Orthopaedic...

17:01
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their investigational sleep/wake regulation agent lemborexant at...

16:30
Therapix Biosciences Ltd. ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase...

16:30
Researchers at Exact Sciences Corp. and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma (HCC), the most common cancer that originates in...

13:55
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced today that elenbecestat was generally safe and well tolerated in a...

12:00
Takeda Canada has joined other industry and government partners by contributing financial support to CATALIS, an important and comprehensive program to promote investment in early clinical research in Quebec. The announcement is being made in advance...

12:00
Takeda Canada s'est jointe à d'autres partenaires de l'industrie et du gouvernement en apportant son soutien financier à CATALIS, un programme complet de grande importance qui fait la promotion de l'investissement dans la recherche clinique précoce...

11:16
L'Oncopole est fier d'annoncer, dans le cadre de son premier concours EMC2, un investissement de près de 12 M$ soutenant sept projets fédérateurs en oncologie au Québec. Cet investissement est possible grâce à une collaboration sans précédent avec...

11:15
The Oncopole is proud to announce, as part of its first EMC2 competition, an investment of close to $12M to support seven oncology projects in Quebec. This investment is made possible thanks to an unprecedented collaboration with leading funders,...

10:49
Kemwell Biopharma, a biologics contract development and manufacturing service provider, announced today that it has signed a contract to manufacture and supply drug substance using its state-of-the-art mammalian cell culture plant in India for Phase...

10:15
Eli Lilly and Company announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). The results showed that patients treated with mirikizumab achieved...

10:00
Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI-PEG 20 in combination with pemetrexed and cisplatin...

09:30
Today at Digestive Disease Week® (DDW), in Washington, D.C., Ferring Pharmaceuticals Inc. will present clinical trial data from 12:00-2:00 p.m. in Hall C of the Walter E. Washington Convention Center. In a poster session, Dr. Lawrence Hookey will...

09:01
miR Scientific, LLC formerly known as miR Diagnostics (miR or the Company), a precision molecular bioscience company, today announces the acceptance of two abstracts and a poster presentation by the American Society of Clinical Oncology (ASCO) at its...

09:00
Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today the successful completion of its initial series of human...

08:30
Abstract #8018  The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented. Of the 84 patients treated in the comparator arm (dexamethasone as a single agent), 44%...

08:30
AbbVie , a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both doses of upadacitinib monotherapy (15 mg and 30 mg) met the primary endpoints of ACR50a at week 12 and clinical...

08:30
Résumé numéro 8018   Les données modélisées sur la survie globale par l'évaluation statistique de l'impact de l'étude croisée (cross-over) ADMYRE ont été présentées.   Sur les 84 patients traités dans le groupe de comparaison (la...

08:30
Ampio Pharmaceuticals, Inc. today announced two peer-reviewed articles on the clinical application of Ampiontm are now available online. "Peer-reviewed journals are an important part of the scientific process, which...

08:14
A new study proves that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in risk of acquisition of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The study, Effectiveness of...

08:02
Montmorency tart cherry juice may play a role in maintaining heart health, suggests a new study published in Food & Function. Researchers at the University of Delaware found that older adults who drank tart cherry juice made from U.S. grown...

08:00
The STATIN trial (RandomiSed conTrolled trial with prAvasTatin versus placebo for preventIoN of preeclampsia) is a European interventional trial, steered by the Fetal Medicine Foundation (FMF) and the Fundación para la Formación e Investigación...

08:00
ReShape Lifesciences Inc. , a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the United States Patent and Trademark Office (USPTO) has granted a method and device patent to the Company...

08:00
Children with Complex Movement Disorders (CMD) see a "significant" improvement after treatment with medical cannabis, a new study using Tikun Olam's high-CBD, low -THC Avidekeltm strain confirms. The study, "Medical...

08:00
To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare -...

07:01
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that enrollment has been completed in the company's ongoing Phase 2...

07:00
Results of a new analysis of real-world safety data presented at a major medical conference in Washington, D.C. show patients given the gut-selective Takeda biologic treatment ENTYVIO® (vedolizumab) had fewer serious infections and adverse events...

07:00
Les résultats d'une nouvelle analyse de données sur l'innocuité provenant de la pratique réelle présentés à un congrès médical de premier plan à Washington, D.C., montrent que les patients ayant reçu ENTYVIO® (vedolizumab), un agent biologique...

06:45
Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination with carboplatin and KEYTRUDA® (pembrolizumab) for the initial...

03:00
Biohaven Pharmaceutical Holding Company Ltd. today announced that expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant, along with other important preclinical and clinical results, will be presented at the American...

02:00
- Patients treated with cemiplimab experienced robust anti-tumour effects[1] - Data also presented today at the 2018 ASCO Annual Meeting[2],[3] - Cemiplimab applications under review by regulatory authorities in the U.S. and...


4 juin 2018

16:53
BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in...

14:15
Patients treated with cemiplimab experienced robust anti-tumor effects Data also presented today at the 2018 ASCO Annual Meeting Cemiplimab applications under review by regulatory authorities in the U.S. and the EU; if approved, would be the third...

14:15
The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the 2018 American Society of Clinical Oncology...

13:27
Résumé #8570  L'essai panier de phase II, qui a commencé avec le recrutement de 15 patients souffrant d'un cancer du poumon à petites cellules, a été étendu après obtention d'une réponse positive et vise désormais la participation de...

10:38
ASCO Abstract #M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 M7824 is an investigational...

10:00
At the American Society Clinical Oncology's 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination...

09:50
Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. today announced that updated efficacy and safety data...

09:32
ASCO Abstract #M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based...

1 2 3 4 5 6 7 8 9 10 11 12 13